Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health Chief Accounting Officer Joseph Ronald Catapano reported routine equity compensation activity. On June 1, 2026, he exercised restricted stock units and performance stock units that converted into a total of 872 shares of common stock at $0.00 per share. On June 2, 2026, 284 shares of common stock were sold at $7.627 per share to cover tax withholding obligations related to these vestings. After these transactions, he directly holds 10,837 shares of Teladoc Health common stock.
Teladoc Health President U.S. Group Health Kelly Bliss reported routine equity compensation activity. On June 1, 2026, she exercised performance and restricted stock units that converted into a total of 15,310 shares of common stock at a conversion price of $0.00 per share.
On June 2, 2026, she sold 7,679 common shares at $7.627 per share to cover the tax withholding obligation tied to these vestings, according to the footnotes. After these transactions, she directly owned 92,378 Teladoc shares, indicating a net increase in her equity position.
Teladoc Health (TDOC) filed a Form 144 notice to sell 9,572 shares of Common Stock tied to restricted stock vesting on 06/01/2026. The filing lists those 9,572 shares as "Restricted Stock Vesting" with the issuer indicated as the source and a compensation origin.
The excerpt also shows prior sales by Fernando Madeira Rodrigues: 25,086 shares sold on 03/03/2026 for $124,972.91, and 5,677 shares sold on 06/02/2026 for $43,298.49. A brokerage line references Fidelity Brokerage Services LLC and $70,832.80 on 06/03/2026.
Tedious, Inc. (TDOC) filing shows a proposed insider sale and recent dispositions. The filing lists 19,132 shares of Common Stock as securities to be sold in connection with Restricted Stock Vesting on 06/01/2026. The filing also discloses prior sales of 50,145 shares on 03/02/2026 for $256,576.92 and 27,731 shares on 03/11/2026 for $152,251.51 by Charles Divita.
The filing is a Form 144 notice reporting a proposed sale of 5,677 shares of Common Stock tied to restricted stock vesting on 06/01/2026. It also lists prior reported dispositions by Fernando Madeira Rodrigues of 16,314 shares on 03/02/2026 and 25,086 shares on 03/03/2026, with proceeds shown as $83,473.84 and $124,972.91, respectively.
Adam Vandervoort submitted a Form 144 reporting an intended sale of 7,906 shares of Common stock following a restricted stock vesting on 06/01/2026. The filing also discloses a prior sale of 27,083 shares on 03/02/2026.
Fidelity Brokerage Services LLC submitted a Form 144 notice concerning Common shares that vested under a restricted stock arrangement on 06/01/2026. The filing lists a prior sale by Kelly Bliss of 26,647 Common shares on 03/02/2026 with an associated monetary figure of $136,344.70.
The record shows broker information for Fidelity at 900 Salem Street, Smithfield RI and an exchange designation of NYSE. The filing is a routine Rule 144 notice of sale related to compensation vesting.
Carlos Nueno Plana submitted a Form 144 notice relating to the proposed sale of 6,196 shares of common stock tied to a restricted stock vesting event dated 06/01/2026. The filing also lists a prior disposition of 20,165 shares on 03/02/2026 for $103,178.25.
The broker listed is Fidelity Brokerage Services LLC in Smithfield, RI. The filing identifies the shares as common stock to be sold on the New York Stock Exchange; the schedule labels the transaction as compensation (vesting). Timing and method of sale beyond these entries are not detailed in the provided excerpt.
Smith Mark Douglas reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health director Mark Douglas Smith received a grant of 30,441 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Teladoc common stock. The RSUs vest in full on the earlier of May 21, 2027 or the day immediately before Teladoc’s 2027 annual shareholder meeting.
Vested shares will be delivered to Smith upon the earliest of several events: within a specified period after separation of service, around the time of a qualifying Change of Control as defined in Teladoc’s Deferred Compensation Plan for Non-Employee Directors, or upon his death. This is a compensation-related equity award, not an open-market stock purchase or sale.
Paulus Kenneth H reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Kenneth H. Paulus received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock. These units vest in full on the earlier of May 21, 2027 or the day before the company’s 2027 annual stockholder meeting, with delivery of vested shares tied to separation of service, a qualifying change of control, or death.